0.2300CADMkt Cap: 63.44M CADP/E: —Last update: 2026-05-22
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat…
Industry Peers
Medical Devices152.25BUSDP/E 24.5
85.88BUSDP/E 24.2
53.45BSEKP/E 22.6
53.33BSEKP/E 98.9
52.13BDKKP/E 22.1
38.61BEURP/E 18.3
23.15BSEK—
22.25BEURP/E 23.4
loading…
Indicators:|
Key Statistics
Company
Market Cap63.44M CAD
Enterprise Value63.71M CAD
Revenue (TTM)816.47K CAD
Gross Profit507.13K CAD
Net Income (TTM)-4.12M CAD
Revenue/Share0.0030 CAD
Last Price0.2300 CAD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountryCA
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-23.50
PEG—
EV/EBITDA-15.91
EV/Revenue78.04
P/S79.39
P/B58.75
EPS (TTM)-0.02
EPS (Forward)-0.01
52W Range
0.23000% of range0.2400
52W High0.2400 CAD
52W Low0.2300 CAD
Profitability
Gross Margin62.11%
Oper. Margin-306.57%
EBITDA Margin0.00%
Profit Margin-504.71%
ROE-231.79%
ROA-117.92%
Growth
Revenue Growth-45.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.29M CAD
CapEx (TTM)48.94K CAD
FCF Margin-245.02%
FCF Yield-3.15%
Net Debt275.14K CAD
Net Debt/EBITDA-0.07
Balance Sheet
Debt/Equity0.26
Current Ratio1.25
Quick Ratio0.85
Book Value/Sh0.0040 CAD
Cash/Share0.0010 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)0.7000 CAD
Target Range0.7000 CAD – 0.7000 CAD
# Analysts1
Ownership
Shares Out.275.82M
Float256.76M
Insiders8.29%
Institutions0.00%
Short Interest
Short Ratio6.2d
Short % Out.0.63%
Shares Short35.74K
Short (prev mo.)59.25K
Technical
SMA 500.2878 (-20.1%)
SMA 2000.2337 (-1.6%)
Beta0.67
S&P 52W Chg28.31%
Avg Vol (30d)52.66K
Avg Vol (10d)665.01K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—